Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data GT Biopharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
Cost of revenue
0
0
Gross profit
0
0
Research and development
0.98
1.07
9.07
1.67
0.49
9.59
8.81
6.47
5.8
3.47
Selling, general and administrative
8.4
135
12.5
9.79
6.28
47.9
12.4
7.11
8.57
8.95
Operating expenses
9.37
136
250
16.1
57.5
21.3
13.6
Operating income
-9.37
-136
-250
16.1
-6.76
-57.5
-21.3
-13.6
-14.4
-12.4
Interest expense
6.56
8.6
9.12
-2.13
-3
0.72
0.01
0.21
0.13
Interest income
0.04
0.29
0.78
0.4
0.12
Other non-operating income
19.1
-8.6
-9.12
22.6
-21.5
-0.5
0.37
5.98
1.2
-15.9
Pre-tax income
9.77
-144
-259
-38.6
Income tax
0
0
0
0
Net income to minority interests
0
0
Net income
9.77
-144
-259
-38.6
-28.3
-58
-20.9
-7.6
-13.2
-28.4
EBITDA
-9.37
-136
-250
16.1
-6.76
EPS, basic
119.91
-8.60
-5.16
-0.01
-6.45
-2.06
-19.66
-5.64
-6.94
-6.68
EPS, diluted
119.91
-8.60
-5.16
-0.01
-6.45
-2.06
-19.66
-5.64
-6.94
-6.68
Shares, basic (weighted)
0.08
0.02
0.05
4.39
28.2
1.06
1.35
1.9
5.51
Shares, diluted (weighted)
0.08
0.02
0.05
3.38
4.39
28.2
1.06
1.35
1.9
5.51
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.02
0.58
0.06
0.03
5.3
8.97
5.67
1.08
3.95
6.81
Short-term investments
0
23
10.8
12.9
Other current assets
0
0
0.03
0.25
0.36
0.19
0.05
0.08
0.19
0.57
Total current assets
0.02
0.58
0.09
0.27
5.66
32.2
16.6
14.1
4.23
8.11
Property, plant and equipment
0
0.01
0.04
0
Lease right-of-use assets
0
0.11
0
0.17
0.05
Goodwill
0
Intangible assets
0
Other non-current assets
0.12
Total assets
0.03
254
25.4
0.4
5.66
32.2
16.7
14.1
4.23
8.11
Accounts payable
2.1
2.55
1.76
1.94
2.24
8.19
3.14
4.33
3.85
0.75
Accrued liabilities
0.22
0.1
1.02
2.38
1.3
1.9
1.67
1.2
1.8
1.56
Total current liabilities
18.9
2.68
14
19.7
35.1
10.3
4.94
6.63
5.9
2.32
Lease liabilities
0.06
Total liabilities
18.9
2.68
14
19.7
35.3
10.3
5
6.63
5.9
2.32
Paid-in capital
106
521
540
548
566
674
686
690
694
730
Retained earnings
-125
-269
-529
-567
-596
-654
-674
-682
-695
-724
Shareholders' equity
-18.9
252
11.4
-19.3
-29.4
21.9
11.7
7.48
-1.67
5.79
Minority interests
-0.17
-0.17
-0.17
-0.17
-0.17
Total equity
-0.17
252
11.2
-19.5
-29.6
21.9
11.7
7.48
-1.67
5.79
Total liabilities and equity
0.03
254
25.4
0.4
5.66
32.2
16.7
14.1
4.23
8.11
Shares outstanding
0.1
50.1
50.7
4.1
5.22
32.1
1.09
1.38
2.23
25.5
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
9.77
-144
-259
-38.6
-28.3
-58
-20.9
-7.6
-13.2
-28.4
Depreciation and amortization
0
0
0.01
0
0
Stock-based compensation
6.59
130
9.7
5.31
0.27
33.9
7.7
0.23
0.43
Change in inventory
0
0
Change in payables
2.81
1.41
0.14
3.15
-0.84
Cash from operations
-1.93
-5.43
-10.7
-3.66
-7.26
-15.6
-15.2
-8.85
-12.9
-12.9
Capital expenditures
0
-0
-0.04
0
Purchases of investments
-23
Cash from investing
0
-0
-0.04
0.2
0
-23
12.1
-2.01
12.9
Stock issued
24.7
6.27
Dividends paid
-0.23
Cash from financing
1.9
5.99
10.2
3.43
12.5
42.3
-0.22
6.27
2.98
15.8
Net change in cash
-0.03
0.56
-0.52
-0.03
5.27
3.67
-3.3
-4.59
2.97
2.86
Free cash flow
-1.93
-5.43
-10.7
-3.66
Interest paid
0
0
0
0.21
Income taxes paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.89 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-133.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Growth
Metric
Value
How it is calculated
Book value CAGR, 3y
-21.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
91.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-21.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
7.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
190.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
73.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.61x
Current assets / current liabilities.
Quick ratio
2.24x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.24x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.37
Cash from operations / diluted weighted shares.
Book value per share
$0.08
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
87.1x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
87.1x
Market cap / tangible book value, when positive.
Earnings yield
-1.5%
Net income / market cap (the inverse of P/E).
Was GT Biopharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $28.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.